AbCellera, a technology leader in therapeutic antibody discovery from natural immune repertoires, announced a multi-target and multi-year collaboration with Novartis. Under the agreement, AbCellera will apply its expertise in antibody discovery and its single-cell screening technology to advance programs on up to ten targets elected by the pharmaceutical partner.
AbCellera continues to build its reputation as a high-powered innovation shop and the premier provider for therapeutic antibody discovery from natural immune responses. This partnership with Novartis marks an important evolution of our partnering strategy, expanding from target-based collaborations to deal structures that encourage long-term relationships and provide extended technology access to select partners,
said Carl Hansen,
President and CEO of AbCellera.
Over the past three years, AbCellera has successfully completed more than thirty antibody discovery programs, including deals with seven global pharmaceutical companies and top-tier public and venture-backed biotech companies. Applying best-in-class technology and custom innovation to each project, AbCellera enables programs for any target class, including difficult multi-pass membrane proteins, and provides its partners with a competitive advantage through superior diversity, speed, and quality.
Under the terms of the agreement with Novartis, AbCellera is eligible to receive technology access, research funding, downstream milestone payments, and royalties on net sales of products.